Takenobu Shimada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takenobu Shimada has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Daiju Fukuda
Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine
15 shared publicationsAtsushi Shibata
Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine
7 shared publicationsKenichiro Otsuka
Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine
7 shared publications- Kenichiro Otsuka
Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine
7 shared publications Asahiro Ito
Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine
6 shared publicationsHiroyuki Tanaka
Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan
6 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Japanese Circulation Society in Circulation Reports
- p. CR-26-0209
Does Electrocardiogram-Based Artificial Intelligence Detect Aortic Stenosis Solely Through Conventional Left Ventricular Hypertrophy Voltage Criteria? ― An Analysis of the Clinical Deep Data Accumulation System (CLIDAS) Database ―
Background: Aortic stenosis (AS) is a progressive valvular disease associated with poor prognosis once symptoms develop, yet routine echocardiographic screening is impractical. While artificial intelligence (AI)-based electrocardiogram (ECG) models have shown promise for AS detection, it remains unclear whether they primarily reflect conventional left ventricular hypertrophy (LVH) voltage criteria or capture additional ECG features.Methods and Results: We developed a deep learning model using 244,816 ECGs from 51,713 patients across 6 academic institutions in Japan (Clinical Deep Data Accumulation System [CLIDAS] database). AS labels were derived from inpatient Diagnosis Procedure Combination (DPC) codes. The model achieved an area under the receiver operating characteristic curve (AUC) of 0.849 (95% confidence interval 0.832–0.865) in the independent test cohort, with consistent performance across institutions, sex, and age. At a threshold of 0.1, sensitivity was 79.1%, specificity was 73.9%, and negative predictive value (NPV) was 98.0%. Conventional LVH voltage criteria (Sokolow–Lyon AUC 0.706; Cornell AUC 0.692) showed lower performance, and adding them to the AI model conferred no incremental benefit (AUC 0.849 vs. 0.847). Gradient-weighted class activation mapping (Grad-CAM) revealed predominant attention around QRS complexes in limb leads, beyond regions typically assessed in LVH evaluation.Conclusions: This multicenter AI-ECG model demonstrated strong discrimination for AS and captured ECG features beyond conventional LVH voltage criteria. The high NPV suggests it may be useful as a rule-out tool.
- 27 October 2026
- Published by Japanese Circulation Society in Circulation Reports
- p. CR-26-0209
Open AccessDoes Electrocardiogram-Based Artificial Intelligence Detect Aortic Stenosis Solely Through Conventional Left Ventricular Hypertrophy Voltage Criteria? ― An Analysis of the Clinical Deep Data Accumulation System (CLIDAS) Database ―
Background: Aortic stenosis (AS) is a progressive valvular disease associated with poor prognosis once symptoms develop, yet routine echocardiographic screening is impractical. While artificial intelligence (AI)-based electrocardiogram (ECG) models have shown promise for AS detection, it remains unclear whether they primarily reflect conventional left ventricular hypertrophy (LVH) voltage criteria or capture additional ECG features.Methods and Results: We developed a deep learning model using 244,816 ECGs from 51,713 patients across 6 academic institutions in Japan (Clinical Deep Data Accumulation System [CLIDAS] database). AS labels were derived from inpatient Diagnosis Procedure Combination (DPC) codes. The model achieved an area under the receiver operating characteristic curve (AUC) of 0.849 (95% confidence interval 0.832–0.865) in the independent test cohort, with consistent performance across institutions, sex, and age. At a threshold of 0.1, sensitivity was 79.1%, specificity was 73.9%, and negative predictive value (NPV) was 98.0%. Conventional LVH voltage criteria (Sokolow–Lyon AUC 0.706; Cornell AUC 0.692) showed lower performance, and adding them to the AI model conferred no incremental benefit (AUC 0.849 vs. 0.847). Gradient-weighted class activation mapping (Grad-CAM) revealed predominant attention around QRS complexes in limb leads, beyond regions typically assessed in LVH evaluation.Conclusions: This multicenter AI-ECG model demonstrated strong discrimination for AS and captured ECG features beyond conventional LVH voltage criteria. The high NPV suggests it may be useful as a rule-out tool.
- Open Access
- 19 October 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
Finerenone versus Steroidal MRAs in Type 2 Diabetes and Chronic Kidney Disease without Prior Heart Failure
Aims: Type 2 diabetes (T2D) and chronic kidney disease (CKD) markedly increase the risk of heart failure (HF) and death. While finerenone improves outcomes in clinical trials, real-world evidence and direct comparisons with steroidal mineralocorticoid receptor antagonists (MRAs) are limited. We evaluated finerenone versus steroidal MRAs (spironolactone and eplerenone) in patients without prior HF. Methods: Using the TriNetX platform, we conducted a retrospective multi-center observational study. We identified patients aged ≥18 years with T2D and CKD without prior HF and ischemic heart disease, who initiated MRAs after receiving a sodium-glucose co-transporter 2 (SGLT2) inhibitor as first-line therapy between 2021 and 2024 (N=3,680). Of these, 724 initiated finerenone and 1,542 initiated a steroidal MRA. After propensity score matching, each group included 551 patients. The primary outcome was all-cause death during the 18-month follow-up period; the secondary outcome was new-onset HF and renal outcome (a composite of end-stage renal disease and dialysis). Results: Over 18-month, finerenone initiation was associated with lower incidence rates of all-cause death (2.1 vs 4.5 events/100 person-years; incidence rate difference, −2.41; 95% CI, −4.38 to −0.44) and new-onset HF (6.5 vs 12.9; −6.38; 95% CI, −9.75 to −3.02), whereas no significant difference was observed for the renal outcome (8.3 vs 9.1; −0.81; 95% CI, −3.99 to 2.37). Conclusions: Finerenone was associated with a lower 18-month risk of all-cause death compared with steroidal MRAs in patients aged ≥18 years with T2D and CKD without prior HF, who received an SGLT2 inhibitor as first-line therapy; however, residual confounding cannot be excluded, and these findings should be considered hypothesis-generating.
- 19 October 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
Open AccessFinerenone versus Steroidal MRAs in Type 2 Diabetes and Chronic Kidney Disease without Prior Heart Failure
Aims: Type 2 diabetes (T2D) and chronic kidney disease (CKD) markedly increase the risk of heart failure (HF) and death. While finerenone improves outcomes in clinical trials, real-world evidence and direct comparisons with steroidal mineralocorticoid receptor antagonists (MRAs) are limited. We evaluated finerenone versus steroidal MRAs (spironolactone and eplerenone) in patients without prior HF. Methods: Using the TriNetX platform, we conducted a retrospective multi-center observational study. We identified patients aged ≥18 years with T2D and CKD without prior HF and ischemic heart disease, who initiated MRAs after receiving a sodium-glucose co-transporter 2 (SGLT2) inhibitor as first-line therapy between 2021 and 2024 (N=3,680). Of these, 724 initiated finerenone and 1,542 initiated a steroidal MRA. After propensity score matching, each group included 551 patients. The primary outcome was all-cause death during the 18-month follow-up period; the secondary outcome was new-onset HF and renal outcome (a composite of end-stage renal disease and dialysis). Results: Over 18-month, finerenone initiation was associated with lower incidence rates of all-cause death (2.1 vs 4.5 events/100 person-years; incidence rate difference, −2.41; 95% CI, −4.38 to −0.44) and new-onset HF (6.5 vs 12.9; −6.38; 95% CI, −9.75 to −3.02), whereas no significant difference was observed for the renal outcome (8.3 vs 9.1; −0.81; 95% CI, −3.99 to 2.37). Conclusions: Finerenone was associated with a lower 18-month risk of all-cause death compared with steroidal MRAs in patients aged ≥18 years with T2D and CKD without prior HF, who received an SGLT2 inhibitor as first-line therapy; however, residual confounding cannot be excluded, and these findings should be considered hypothesis-generating.
- Open Access
- 6 October 2026
- Published by Elsevier in Resuscitation
Prehospital prognostication after out-of-hospital cardiac arrest in tertiary care centers: the R-EDByUS score in the JAAM-OHCA registry
- 6 October 2026
- Published by Elsevier in Resuscitation
Open AccessPrehospital prognostication after out-of-hospital cardiac arrest in tertiary care centers: the R-EDByUS score in the JAAM-OHCA registry
- 15 June 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (10) , 1214-1221
In-hospital nighttime blood pressure and heart failure hospitalization after discharge in chronic coronary disease
Background: Nighttime blood pressure provides prognostic information beyond conventional measurements, but routine nocturnal assessment remains uncommon. We investigated whether automated nighttime blood pressure is associated with subsequent heart failure hospitalization in chronic coronary disease. Methods: We conducted a single-center retrospective study of hospitalized patients with chronic coronary disease who underwent automated nighttime blood pressure monitoring between July 2013 and October 2017. After excluding 66 patients with insufficient measurements, 485 were analyzed. Blood pressure was recorded hourly from 23:00 to 06:00. The primary endpoint was the first heart failure hospitalization after discharge, with all-cause death as a competing event; the secondary endpoint was all-cause mortality. Results: Median age was 69 years, and 360 patients were men. Nocturnal hypertension was present in 301 patients. During a median follow-up of 4.2 years, 50 patients experienced heart failure hospitalization and 31 died. At 4 years, the cumulative incidence of heart failure hospitalization was 7.4% versus 2.2% in patients with versus without nocturnal hypertension, and that of all-cause death was 7.7% versus 4.0%. Per 10-mmHg higher mean nocturnal systolic blood pressure, the subdistribution hazard ratio for heart failure hospitalization was 1.24 (95% CI, 1.08-1.42), or 1.19 (1.04-1.37) after adjustment for office systolic blood pressure; the corresponding subdistribution hazard ratio for office systolic blood pressure was 1.24 (0.99-1.55). Conclusions: Higher pre-discharge mean nocturnal systolic blood pressure was associated with subsequent heart failure hospitalization in chronic coronary disease. Automated in-hospital nighttime blood pressure monitoring may help identify patients at increased post-discharge heart failure risk.
- 15 June 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (10) , 1214-1221
In-hospital nighttime blood pressure and heart failure hospitalization after discharge in chronic coronary disease
Background: Nighttime blood pressure provides prognostic information beyond conventional measurements, but routine nocturnal assessment remains uncommon. We investigated whether automated nighttime blood pressure is associated with subsequent heart failure hospitalization in chronic coronary disease. Methods: We conducted a single-center retrospective study of hospitalized patients with chronic coronary disease who underwent automated nighttime blood pressure monitoring between July 2013 and October 2017. After excluding 66 patients with insufficient measurements, 485 were analyzed. Blood pressure was recorded hourly from 23:00 to 06:00. The primary endpoint was the first heart failure hospitalization after discharge, with all-cause death as a competing event; the secondary endpoint was all-cause mortality. Results: Median age was 69 years, and 360 patients were men. Nocturnal hypertension was present in 301 patients. During a median follow-up of 4.2 years, 50 patients experienced heart failure hospitalization and 31 died. At 4 years, the cumulative incidence of heart failure hospitalization was 7.4% versus 2.2% in patients with versus without nocturnal hypertension, and that of all-cause death was 7.7% versus 4.0%. Per 10-mmHg higher mean nocturnal systolic blood pressure, the subdistribution hazard ratio for heart failure hospitalization was 1.24 (95% CI, 1.08-1.42), or 1.19 (1.04-1.37) after adjustment for office systolic blood pressure; the corresponding subdistribution hazard ratio for office systolic blood pressure was 1.24 (0.99-1.55). Conclusions: Higher pre-discharge mean nocturnal systolic blood pressure was associated with subsequent heart failure hospitalization in chronic coronary disease. Automated in-hospital nighttime blood pressure monitoring may help identify patients at increased post-discharge heart failure risk.
- Open Access
Does ECG-Based AI Detect Aortic Stenosis Beyond Conventional LVH Criteria? An Analysis of the CLIDAS Database
Background: Aortic stenosis (AS) is a progressive valvular disease associated with poor prognosis once symptoms develop, yet routine echocardiographic screening is impractical. While artificial intelligence (AI)-based electrocardiogram (ECG) models have shown promise for AS detection, it remains unclear whether they primarily reflect conventional left ventricular hypertrophy (LVH) voltage criteria or capture additional ECG features. Methods and Results: We developed a deep learning model using 244,816 ECGs from 51,713 patients across six academic institutions in Japan (CLIDAS database). AS labels were derived from inpatient Diagnosis Procedure Combination (DPC) codes. The model achieved an area under the receiver operating characteristic curve (AUC) of 0.849 (95% confidence interval 0.832–0.865) in the independent test cohort, with consistent performance across institutions, sex, and age. At a threshold of 0.1, sensitivity was 79.1%, specificity was 73.9%, and negative predictive value (NPV) was 98.0%. Conventional LVH voltage criteria (Sokolow–Lyon AUC 0.706; Cornell AUC 0.692) showed lower performance, and adding them to the AI model conferred no incremental benefit (AUC 0.849 vs. 0.847). Gradient-weighted class activation mapping (Grad-CAM) revealed predominant attention around QRS complexes in limb leads, beyond regions typically assessed in LVH evaluation. Conclusions: This multicenter AI-ECG model demonstrated strong discrimination for AS and captured ECG features beyond conventional LVH voltage criteria. The high NPV supports its use as a rule-out pre-screening tool.
Open AccessDoes ECG-Based AI Detect Aortic Stenosis Beyond Conventional LVH Criteria? An Analysis of the CLIDAS Database
Background: Aortic stenosis (AS) is a progressive valvular disease associated with poor prognosis once symptoms develop, yet routine echocardiographic screening is impractical. While artificial intelligence (AI)-based electrocardiogram (ECG) models have shown promise for AS detection, it remains unclear whether they primarily reflect conventional left ventricular hypertrophy (LVH) voltage criteria or capture additional ECG features. Methods and Results: We developed a deep learning model using 244,816 ECGs from 51,713 patients across six academic institutions in Japan (CLIDAS database). AS labels were derived from inpatient Diagnosis Procedure Combination (DPC) codes. The model achieved an area under the receiver operating characteristic curve (AUC) of 0.849 (95% confidence interval 0.832–0.865) in the independent test cohort, with consistent performance across institutions, sex, and age. At a threshold of 0.1, sensitivity was 79.1%, specificity was 73.9%, and negative predictive value (NPV) was 98.0%. Conventional LVH voltage criteria (Sokolow–Lyon AUC 0.706; Cornell AUC 0.692) showed lower performance, and adding them to the AI model conferred no incremental benefit (AUC 0.849 vs. 0.847). Gradient-weighted class activation mapping (Grad-CAM) revealed predominant attention around QRS complexes in limb leads, beyond regions typically assessed in LVH evaluation. Conclusions: This multicenter AI-ECG model demonstrated strong discrimination for AS and captured ECG features beyond conventional LVH voltage criteria. The high NPV supports its use as a rule-out pre-screening tool.
- Open Access
- 23 December 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 231, 113072
Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin
- 23 December 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 231, 113072
Open AccessMajor adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin
- Open Access
- 19 November 2025
- Published by Elsevier in Resuscitation
- Vol. 217, 110888
Corrigendum to “Neurological prognosis prediction upon arrival at the hospital after out-of-hospital cardiac arrest: R-EDByUS score”. [Resuscitation 200 (2024) 110257]
- 19 November 2025
- Published by Elsevier in Resuscitation
- Vol. 217, 110888
Open AccessCorrigendum to “Neurological prognosis prediction upon arrival at the hospital after out-of-hospital cardiac arrest: R-EDByUS score”. [Resuscitation 200 (2024) 110257]
- Open Access
- 18 August 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (9) , 102074
Clinical Outcomes of Ezetimibe Plus Statins in Patients With Lower Extremity Artery Disease
- 18 August 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (9) , 102074
Open AccessClinical Outcomes of Ezetimibe Plus Statins in Patients With Lower Extremity Artery Disease
- 15 July 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 439, 133615
Reply to “Reframing the CHADS-P2A2RC score in chronic coronary syndrome: From ischemic risk stratification to a signal for caution”
- 15 July 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 439, 133615
Reply to “Reframing the CHADS-P2A2RC score in chronic coronary syndrome: From ischemic risk stratification to a signal for caution”
- Open Access
- 10 June 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 3 (2) , qyaf079
High levels of pericoronary adipose tissue inflammation are associated with coronary atherosclerosis independent of epicardial adipose tissue volume in patients with chronic coronary syndrome
Aims: This study aimed to assess clinical risks and coronary atherosclerotic burden in patients with chronic coronary syndrome (CCS) stratified by pericoronary artery adipose tissue (PCAT) composition and epicardial adipose tissue volume (EAV). Methods and results: We retrospectively included 410 CCS patients who underwent coronary computed tomography angiography. Patients were divided into four groups based on an EAV index ≥ 73.5 mL/mm2 and PCAT attenuation (PCATA) in the right coronary artery (PCATARCA) ≥ −76.6 HU (above median); Groups A (low EAV index and low PCATARCA), B (low EAV index and high PCATARCA), C (high EAV index and low PCATARCA), and D (high EAV index and high PCATARCA). Multivariable models assessed the relative risk of coronary artery calcium score (CACS) > 400 and coronary artery disease (CAD), and predictors of coronary plaque volume. The log-transformed CACS increased progressively, with Group D showing the highest values. Group D had the highest prevalence of Hisayama risk score of 10-year risk > 10%, CACS > 400, and CAD. The high EAVi group (C and D) showed increased risks of CACS > 400 [Group C: adjusted odds ratio, 6.30; 95% confidence interval (CI), 1.39–28.6; Group D: adjusted odds ratio, 9.13; 95% CI, 2.00–41.5] and CAD (Group C: adjusted odds ratio, 2.33; 95% CI, 1.13–4.83; Group D: adjusted odds ratio, 9.13; 95% CI, 2.00–41.5). Multivariate linear regression analysis demonstrated that PCATARCA was associated with a greater plaque volume independent of EAV index. Conclusion: Elevated PCAT inflammation is associated with the coronary plaque burden independent of EAV index in patients with CCS. Lay summary: • This study demonstrates that distinct phenotypes based on ectopic fat volume and composition—the volume of epicardial adipose tissue (EAT) and the inflammation status of pericoronary adipose tissue (PCAT)—can characterize coronary atherosclerotic disease burden in patients with chronic coronary syndrome. • While both increased EAT volume and PCAT inflammation have been reportedly associated with coronary artery disease (CAD) and cardiovascular events, evidence investigating the association of EAT volume and PCAT inflammation with CAD disease burden is limited. • Patients with increased EAT volume are at an elevated risk for coronary artery calcification and increased plaque burden, regardless of PCAT inflammation. In contrast, among patients without increased EAT volume, increased PCAT inflammation is correlated with an increased risk of coronary artery calcification and plaque burden.
- 10 June 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 3 (2) , qyaf079
Open AccessHigh levels of pericoronary adipose tissue inflammation are associated with coronary atherosclerosis independent of epicardial adipose tissue volume in patients with chronic coronary syndrome
Aims: This study aimed to assess clinical risks and coronary atherosclerotic burden in patients with chronic coronary syndrome (CCS) stratified by pericoronary artery adipose tissue (PCAT) composition and epicardial adipose tissue volume (EAV). Methods and results: We retrospectively included 410 CCS patients who underwent coronary computed tomography angiography. Patients were divided into four groups based on an EAV index ≥ 73.5 mL/mm2 and PCAT attenuation (PCATA) in the right coronary artery (PCATARCA) ≥ −76.6 HU (above median); Groups A (low EAV index and low PCATARCA), B (low EAV index and high PCATARCA), C (high EAV index and low PCATARCA), and D (high EAV index and high PCATARCA). Multivariable models assessed the relative risk of coronary artery calcium score (CACS) > 400 and coronary artery disease (CAD), and predictors of coronary plaque volume. The log-transformed CACS increased progressively, with Group D showing the highest values. Group D had the highest prevalence of Hisayama risk score of 10-year risk > 10%, CACS > 400, and CAD. The high EAVi group (C and D) showed increased risks of CACS > 400 [Group C: adjusted odds ratio, 6.30; 95% confidence interval (CI), 1.39–28.6; Group D: adjusted odds ratio, 9.13; 95% CI, 2.00–41.5] and CAD (Group C: adjusted odds ratio, 2.33; 95% CI, 1.13–4.83; Group D: adjusted odds ratio, 9.13; 95% CI, 2.00–41.5). Multivariate linear regression analysis demonstrated that PCATARCA was associated with a greater plaque volume independent of EAV index. Conclusion: Elevated PCAT inflammation is associated with the coronary plaque burden independent of EAV index in patients with CCS. Lay summary: • This study demonstrates that distinct phenotypes based on ectopic fat volume and composition—the volume of epicardial adipose tissue (EAT) and the inflammation status of pericoronary adipose tissue (PCAT)—can characterize coronary atherosclerotic disease burden in patients with chronic coronary syndrome. • While both increased EAT volume and PCAT inflammation have been reportedly associated with coronary artery disease (CAD) and cardiovascular events, evidence investigating the association of EAT volume and PCAT inflammation with CAD disease burden is limited. • Patients with increased EAT volume are at an elevated risk for coronary artery calcification and increased plaque burden, regardless of PCAT inflammation. In contrast, among patients without increased EAT volume, increased PCAT inflammation is correlated with an increased risk of coronary artery calcification and plaque burden.